Cashu
BioAffinity Technologies' CyPath® Lung Tool Enhances Lung Cancer Detection for Veterans' Healthcare
over 1 year ago
Stocks
Health Care
biaf
BioAffinity Technologies
NASDAQ: BIAF
-0.30 (-10.95%)
2.44
USD
At close at Mar 18, 20:45 UTC
Overview
Loading chart...
Key Stats
Market Cap
12.33M
Dividend Yield
0.00%
P/E Ratio
-0.83
EPS
-0.71
Revenue
8.81M
Avg. Volume
74.41M
About
What does BIAF do?
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.